♥

Sequent Scientific Limited

ISIN : INE807F01027
NSE : SEQUENT
BSE : 512529
Face Value : 2
Industry : Pharmaceuticals & Drugs

EPS : -1.44
EPS (TTM) : 0.21
Price to Earning (P/E) : -90.85
Book Value : 23.22
Price to Bookvalue (P/B) : 5.63
Dividend Yield : 0 %
Return on Equity (ROE) : -4.85 %
Return on Capital Employed (ROCE) : -0.60 %

Sequent Scientific share price (02-Apr-2026)
National Stock Exchange NSE
Open / Close	0 - 0 NAN %
Low / High	0 - 0 NAN %
Trade Volume	0
52 Week Low / High	0 - 0 NAN %
Bombay Stock Exchange BSE
Open / Close	189.1 - 191.85 1.5 %
Low / High	186 - 192.5 3.5 %
Trade Volume	16,371
52 Week Low / High	141.8 - 260.3 83.6 %

YOU MAY ALSO LIKE

How much money do you need to retire
Know how much money do you need to retire, before how much to invest ?
Stock market course tutorial
Stock Market Investment Course explained in simple words.
CAGR Calculator
Check your investment returns using our CAGR / Investment Growth Calculator
Low PE ratio stocks
Undervalued, low PE ratio stocks on Stock exchange NSE and BSE
Share Market basics for beginners
Share Market jargons in simple terms
High dividend stocks
High dividend yield stocks on Stock exchange NSE and BSE

Consolidated Standalone

CONSOLIDATED QUARTERLY RESULT FOR SEQUENT SCIENTIFIC LIMITED

Date End	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024
No of months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months
Net Sales	3837.09	3413.21	3376.07	3753.13	3666.68	3332.08	3459.67	3293.59	3611.97	3902.1
Total Income	3874.79	3422	3385.18	3781.76	3684.05	3340.01	3476.15	3338.77	3651.95	3928.9
Total Expenditure	3503.63	3392.05	3347.37	3649.76	3700.36	3414.44	3308.36	3071.1	3289.27	3482.6
Other Income	37.7	8.79	9.11	28.63	17.37	7.93	16.48	45.18	39.98	26.8
Operating Profit	371.16	29.95	37.81	132	-16.31	-74.43	167.79	267.67	362.68	446.3
Interest	60.38	68.01	81.21	97.25	108.7	104.84	125.8	125.81	124.41	163.8
Exceptional Items		-31.98			-615.96	-235.11	80.67	27.6	-47.07
PBDT	310.78	-70.04	-43.4	34.75	-740.97	-414.38	122.66	169.46	191.2	282.5
Depreciation	124.71	125.62	133.84	136.74	147.05	142.41	153.6	154.55	164.84	162.5
Profit Before Tax	186.07	-195.66	-177.24	-101.99	-888.02	-556.79	-30.94	14.91	26.36	120
Tax	85.71	-51.6	-132.83	-4.22	36.38	-209.98	37.88	-91.85	13.62	29.4
Profit After Tax	100.36	-144.06	-44.41	-97.77	-924.4	-346.81	-68.82	106.76	12.74	90.6
Net Profit	100.36	-144.06	-44.41	-97.77	-924.4	-346.81	-68.82	106.76	12.74	90.6
Equity Capital	496.74	498.87	498.87	498.87	498.86	498.87	498.86	498.86	498.86	499
Face Value (IN RS)	2	2	2	2	2	2	2	2	2	2
Calculated EPS	0.36	-0.56	-0.15	-0.36	-3.75	-1.4	-0.34	0.33	-0.04	0.26
Diluted Eps After Extraordinary Items	0.36	-0.57	-0.15	-0.36	-3.77	-1.4	-0.34	0.33	-0.04	0.26
Diluted Eps Before Extraordinary Items	0.36	-0.57	-0.15	-0.36	-3.77	-1.4	-0.34	0.33	-0.04	0.26

STANDALONE QUARTERLY RESULT FOR SEQUENT SCIENTIFIC LIMITED

Date End	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024
No of months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months
Net Sales	636.73	648.6	542.31	569.99	465.95	404.23	491.19	422.05	367.71	576.7
Total Income	694.45	707.4	609.57	646.22	546.08	501.18	589.85	556.49	497.46	685.1
Total Expenditure	584.59	668.5	638.1	657.45	526.4	494.9	568.19	463.61	425.12	596.5
Other Income	57.72	58.8	67.26	76.23	80.13	96.95	98.66	134.44	129.75	108.4
Operating Profit	109.86	38.9	-28.53	-11.23	19.68	6.28	21.66	92.88	72.34	88.6
Interest	6.08	3.54	5.75	7.17	8.67	9.82	12.09	11.45	10.25	8.1
Exceptional Items						-62.54
PBDT	103.78	35.36	-34.28	-18.4	11.01	-66.08	9.57	81.43	62.09	80.5
Depreciation	23.41	23.81	22.49	21.54	23.31	24.25	23.53	20.53	21.09	20
Profit Before Tax	80.37	11.55	-56.77	-39.94	-12.3	-90.33	-13.96	60.9	41	60.5
Tax	13.89	3.15	-16.27	-27.69	4.15	-22.3	-4.78	15.1	3.37	15.5
Profit After Tax	66.48	8.4	-40.5	-12.25	-16.45	-68.03	-9.18	45.8	37.63	45
Net Profit	66.48	8.4	-40.5	-12.25	-16.45	-68.03	-9.18	45.8	37.63	45
Equity Capital	496.74	498.87	498.87	498.87	498.87	498.87	498.86	498.86	498.86	499
Face Value (IN RS)	2	2	2	2	2	2	2	2	2	2
Calculated EPS	0.27	0.03	-0.16	-0.05	-0.07	-0.27	-0.04	0.18	0.15	0.18
Diluted Eps After Extraordinary Items	0.27	0.03	-0.16	-0.05	-0.07	-0.27	-0.04	0.18	0.15	0.18
Diluted Eps Before Extraordinary Items	0.27	0.03	-0.16	-0.05	-0.07	-0.27	-0.04	0.18	0.15	0.18

Consolidated Standalone

CONSOLIDATED ANNUAL RESULT FOR SEQUENT SCIENTIFIC LIMITED

Date End	Mar 2022	Mar 2023	Mar 2024
No of months	12 months	12 months	12 months
Net Sales	14128.2	14209.1	13697.3
Total Income	14236.6	14273	13806.9
Total Expenditure	13034.2	14089.5	13083.2
Other Income	108.45	63.9	109.57
Operating Profit	1202.45	183.45	723.71
Interest	157.74	355.17	480.86
Exceptional Items		-647.94	-173.91
PBDT	1044.71	-819.66	68.94
Depreciation	510.85	556.93	615.4
Profit Before Tax	533.86	-1376.59	-546.46
Tax	83.26	-156.81	-250.33
Profit After Tax	450.6	-1219.78	-296.13
Net Profit	450.6	-1219.78	-296.13
Equity Capital	496.74	498.86	498.86
Face Value (IN RS)	2	2	2
Reserves	6427.33	6488.92	6066.74
Calculated EPS	1.66	-4.86	-1.44
Diluted Eps After Extraordinary Items	1.65	-4.88	-1.44
Diluted Eps Before Extraordinary Items	1.65	-4.88	-1.44

STANDALONE ANNUAL RESULT FOR SEQUENT SCIENTIFIC LIMITED

Date End	Mar 2022	Mar 2023	Mar 2024
No of months	12 months	12 months	12 months
Net Sales	2196.26	2226.85	1685.18
Total Income	2472.69	2509.27	2144.98
Total Expenditure	2203.76	2490.45	1951.82
Other Income	276.43	282.42	459.8
Operating Profit	268.93	18.82	193.16
Interest	16.1	25.13	43.61
Exceptional Items			-62.54
PBDT	252.83	-6.31	87.01
Depreciation	95.93	91.15	89.4
Profit Before Tax	156.9	-97.46	-2.39
Tax	8.91	-36.66	-8.61
Profit After Tax	147.99	-60.8	6.22
Net Profit	147.99	-60.8	6.22
Equity Capital	496.74	498.87	498.86
Face Value (IN RS)	2	2	2
Reserves	9914.14	10084.8	10373.4
Calculated EPS	0.6	-0.24	0.02
Diluted Eps After Extraordinary Items	0.59	-0.24	0.03
Diluted Eps Before Extraordinary Items	0.59	-0.24	0.03

Consolidated Standalone

CONSOLIDATED PROFIT / LOSS FOR SEQUENT SCIENTIFIC LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Gross Sales	1387.91 Cr	1412.82 Cr	1454.23 Cr	1411.07 Cr
Sales	1357.51 Cr	1395.94 Cr	1439.43 Cr	1391.19 Cr
Processing Charges / Service Income	20.82 Cr	14.23 Cr	12.17 Cr	16.45 Cr
Net Sales	1361.62 Cr	1412.82 Cr	1420.91 Cr	1369.73 Cr
Increase/Decrease in Stock	-39.03 Cr	-49.42 Cr	18.9 Cr	-29.46 Cr
Raw Material Consumed	733.68 Cr	842.41 Cr	814.87 Cr	789.2 Cr
Opening Raw Materials	86.43 Cr	91.79 Cr	129.05 Cr	141.23 Cr
Purchases Raw Materials	594.03 Cr	707.77 Cr	705.28 Cr	589.14 Cr
Closing Raw Materials	91.79 Cr	129.05 Cr	141.23 Cr	116.7 Cr
Other Direct Purchases / Brought in cost	145.02 Cr	171.89 Cr	121.77 Cr	175.54 Cr
Power & Fuel Cost	28.75 Cr	33.86 Cr	42.45 Cr	35.46 Cr
Electricity & Power	28.75 Cr	33.86 Cr	42.45 Cr	35.46 Cr
Employee Cost	187.22 Cr	231.37 Cr	258.38 Cr	250.57 Cr
Salaries, Wages & Bonus	147.59 Cr	162.97 Cr	182.87 Cr	189.17 Cr
Contributions to EPF & Pension Funds	24.63 Cr	26 Cr	27.65 Cr	27.59 Cr
Workmen and Staff Welfare Expenses	7.77 Cr	9.1 Cr	12.45 Cr	11.58 Cr
Other Manufacturing Expenses	99.3 Cr	93.67 Cr	85.14 Cr	73.58 Cr
Sub-contracted / Out sourced services	0	0	0	5.71 Cr
Processing Charges	55.78 Cr	43.58 Cr	29.87 Cr	16.65 Cr
Repairs and Maintenance	21.88 Cr	21.88 Cr	24.34 Cr	25.51 Cr
General and Administration Expenses	58.4 Cr	66.9 Cr	75.8 Cr	78.1 Cr
Rent , Rates & Taxes	6.36 Cr	7.88 Cr	6.34 Cr	9.05 Cr
Insurance	5.19 Cr	6.45 Cr	7.92 Cr	8.28 Cr
Professional and legal fees	37.09 Cr	40.63 Cr	43.08 Cr	43.45 Cr
Traveling and conveyance	6.53 Cr	8.99 Cr	15.44 Cr	13.69 Cr
Selling and Distribution Expenses	50 Cr	57.11 Cr	58 Cr	56.7 Cr
Advertisement & Sales Promotion	12.16 Cr	18.82 Cr	18.92 Cr	19.41 Cr
Sales Commissions & Incentives	9.58 Cr	8.86 Cr	9.21 Cr	9.18 Cr
Freight and Forwarding	28.26 Cr	29.44 Cr	29.86 Cr	28.12 Cr
Miscellaneous Expenses	31.21 Cr	27.52 Cr	55.42 Cr	54.16 Cr
Bad debts /advances written off	3.03 Cr	44.2 Lk	19.5 Lk	6.2 Lk
Provision for doubtful debts	-2.13 Cr	0	75.6 Lk	1.38 Cr
Loss on disposal of fixed assets(net)	0	6.9 Lk	0	4.5 Lk
Loss on foreign exchange fluctuations	4.22 Cr	0	11.45 Cr	15.37 Cr
Total Expenditure	1149.55 Cr	1303.43 Cr	1408.95 Cr	1308.32 Cr
Other Income	8.36 Cr	10.86 Cr	6.39 Cr	10.96 Cr
Interest Received	62.6 Lk	24.1 Lk	1.21 Cr	67 Lk
Dividend Received	99.5 Lk	16.6 Lk	10,000	0
Profit on sale of Fixed Assets	69.8 Lk	0	2.04 Cr	5.59 Cr
Profits on sale of Investments	2.58 Cr	31.8 Lk	5.1 Lk	1.7 Lk
Provision Written Back	0	1.5 Lk	0	0
Foreign Exchange Gains	0	6.3 Cr	0	0
Operating Profit	220.43 Cr	120.24 Cr	18.34 Cr	72.37 Cr
Interest	24.38 Cr	15.77 Cr	35.52 Cr	48.09 Cr
Interest on Term Loan	0	10.75 Cr	27.27 Cr	44.12 Cr
Bank Charges etc	5.13 Cr	2.26 Cr	5.8 Cr	1.66 Cr
PBDT	196.05 Cr	104.47 Cr	-17.17 Cr	24.28 Cr
Depreciation	50.6 Cr	51.08 Cr	55.69 Cr	61.54 Cr
Profit Before Taxation & Exceptional Items	145.45 Cr	53.39 Cr	-72.86 Cr	-37.26 Cr
Exceptional Income / Expenses	-8.82 Cr	0	-64.79 Cr	-17.39 Cr
Profit Before Tax	136.63 Cr	53.39 Cr	-137.66 Cr	-54.65 Cr
Provision for Tax	32.18 Cr	8.33 Cr	-15.68 Cr	-25.03 Cr
Current Income Tax	32.1 Cr	25.73 Cr	7.84 Cr	14.48 Cr
Deferred Tax	-2.86 Cr	-5.37 Cr	-23.2 Cr	-38.98 Cr
Profit After Tax	104.45 Cr	45.06 Cr	-121.98 Cr	-29.61 Cr
Minority Interest	-9.01 Cr	-3.81 Cr	81.8 Lk	-6.26 Cr
Consolidated Net Profit	95.44 Cr	41.25 Cr	-121.16 Cr	-35.87 Cr
Profit Balance B/F	-79.12 Cr	59.97 Cr	88.59 Cr	99.68 Cr
Appropriations	16.33 Cr	101.22 Cr	-32.57 Cr	63.82 Cr
Other Appropriation	-43.64 Cr	12.33 Cr	-132.25 Cr	-31.9 Cr
Equity Dividend %	25	0	0	0
Earnings Per Share	3.84	1.66	-4.86	-1.44
Adjusted EPS	3.84	1.66	-4.86	-1.44

STANDALONE PROFIT / LOSS FOR SEQUENT SCIENTIFIC LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Gross Sales	268.69 Cr	220.32 Cr	225.18 Cr	172.45 Cr
Sales	265.06 Cr	216.68 Cr	214.76 Cr	161.64 Cr
Processing Charges / Service Income	1.41 Cr	3.34 Cr	9.85 Cr	10.26 Cr
Net Sales	265.46 Cr	219.63 Cr	222.68 Cr	168.52 Cr
Increase/Decrease in Stock	-15.56 Cr	-19.73 Cr	19.42 Cr	5.35 Cr
Raw Material Consumed	124.43 Cr	128.39 Cr	116.5 Cr	102.54 Cr
Opening Raw Materials	11.72 Cr	10.45 Cr	12.95 Cr	12.08 Cr
Purchases Raw Materials	114.61 Cr	126.51 Cr	113.2 Cr	94.98 Cr
Closing Raw Materials	10.45 Cr	12.95 Cr	12.08 Cr	4.52 Cr
Other Direct Purchases / Brought in cost	8.54 Cr	4.38 Cr	2.42 Cr	0
Power & Fuel Cost	12.77 Cr	11.96 Cr	13.93 Cr	12.89 Cr
Electricity & Power	12.77 Cr	11.96 Cr	13.93 Cr	12.89 Cr
Employee Cost	22.42 Cr	27.38 Cr	36.66 Cr	30.05 Cr
Salaries, Wages & Bonus	17.17 Cr	18.6 Cr	22.62 Cr	20.17 Cr
Contributions to EPF & Pension Funds	1.7 Cr	1.88 Cr	1.86 Cr	1.76 Cr
Workmen and Staff Welfare Expenses	99.6 Lk	82.4 Lk	76.2 Lk	69.2 Lk
Other Manufacturing Expenses	60.33 Cr	48.21 Cr	39.3 Cr	22.4 Cr
Processing Charges	50.38 Cr	37.58 Cr	25.77 Cr	13.33 Cr
Repairs and Maintenance	5.77 Cr	6.5 Cr	9.15 Cr	5.84 Cr
General and Administration Expenses	15.28 Cr	16.29 Cr	15.1 Cr	12.12 Cr
Rent , Rates & Taxes	1.12 Cr	1.58 Cr	51.8 Lk	47.7 Lk
Insurance	1.35 Cr	1.9 Cr	2.31 Cr	1.89 Cr
Professional and legal fees	11.81 Cr	11.39 Cr	10.39 Cr	7.95 Cr
Traveling and conveyance	18.1 Lk	19.4 Lk	65.7 Lk	59.2 Lk
Selling and Distribution Expenses	4.02 Cr	2.16 Cr	1.85 Cr	1.55 Cr
Advertisement & Sales Promotion	10.8 Lk	30.7 Lk	2.2 Lk	28.2 Lk
Sales Commissions & Incentives	1.09 Cr	18.2 Lk	13.6 Lk	18.4 Lk
Freight and Forwarding	2.82 Cr	1.67 Cr	1.69 Cr	1.09 Cr
Miscellaneous Expenses	6.48 Cr	16.94 Cr	6.34 Cr	8.29 Cr
Bad debts /advances written off	0	1.7 Lk	0	0
Total Expenditure	230.17 Cr	231.59 Cr	249.09 Cr	195.18 Cr
Other Income	19.97 Cr	38.86 Cr	28.28 Cr	45.98 Cr
Interest Received	10.71 Cr	17.54 Cr	21.79 Cr	34.39 Cr
Dividend Received	99.4 Lk	4.58 Cr	0	0
Profit on sale of Fixed Assets	0	0	0	4.56 Cr
Profits on sale of Investments	1.57 Cr	60,000	0	0
Provision Written Back	2.9 Lk	0	4.3 Lk	0
Foreign Exchange Gains	23 Lk	34.7 Lk	0	12.9 Lk
Operating Profit	55.26 Cr	26.89 Cr	1.88 Cr	19.32 Cr
Interest	2.68 Cr	1.61 Cr	2.51 Cr	4.36 Cr
Interest on Term Loan	0	1.04 Cr	1.82 Cr	3.77 Cr
Bank Charges etc	83.2 Lk	45.7 Lk	60.6 Lk	52.7 Lk
PBDT	52.58 Cr	25.28 Cr	-63.1 Lk	14.96 Cr
Depreciation	9.13 Cr	9.59 Cr	9.12 Cr	8.94 Cr
Profit Before Taxation & Exceptional Items	43.45 Cr	15.69 Cr	-9.75 Cr	6.02 Cr
Exceptional Income / Expenses	-2.56 Cr	0	0	-6.25 Cr
Profit Before Tax	40.89 Cr	15.69 Cr	-9.75 Cr	-23.9 Lk
Provision for Tax	8.77 Cr	89.1 Lk	-3.67 Cr	-86.1 Lk
Current Income Tax	7.3 Cr	2.51 Cr	2 Lk	0
Deferred Tax	2.69 Cr	-10.3 Lk	-3.09 Cr	-1.32 Cr
Profit After Tax	32.11 Cr	14.8 Cr	-6.08 Cr	62.2 Lk
Consolidated Net Profit	32.11 Cr	14.8 Cr	-6.08 Cr	62.2 Lk
Profit Balance B/F	-47.46 Cr	28.03 Cr	30.56 Cr	38.76 Cr
Appropriations	-15.35 Cr	42.83 Cr	24.48 Cr	39.38 Cr
Other Appropriation	-43.38 Cr	12.27 Cr	-14.28 Cr	-2.65 Cr
Equity Dividend %	25	0	0	0
Earnings Per Share	1.29	0.6	-0.24	0.02
Adjusted EPS	1.29	0.6	-0.24	0.02

Consolidated Standalone

CONSOLIDATED CASH FLOW FOR SEQUENT SCIENTIFIC LIMITED

Year End	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Profit Before Tax	145.45 Cr	53.39 Cr	-137.66 Cr	-54.65 Cr
Adjustment	83.98 Cr	93.27 Cr	220.72 Cr	144.97 Cr
Changes In working Capital	-70.89 Cr	-89.3 Cr	-51.61 Cr	-45.67 Cr
Cash Flow after changes in Working Capital	158.55 Cr	57.36 Cr	31.45 Cr	44.65 Cr
Cash Flow from Operating Activities	114.75 Cr	30.6 Cr	16.81 Cr	30.6 Cr
Cash Flow from Investing Activities	9.65 Cr	-95.57 Cr	-64.96 Cr	-5.92 Cr
Cash Flow from Financing Activitie	-138.75 Cr	67.26 Cr	32.23 Cr	-1.44 Cr
Net Cash Inflow / Outflow	-14.35 Cr	2.29 Cr	-15.92 Cr	23.24 Cr
Opening Cash & Cash Equivalents	68.1 Cr	53.74 Cr	57.5 Cr	41.57 Cr
Cash & Cash Equivalent of Subsidiaries under liquidations	0	1.47 Cr	0	0
Closing Cash & Cash Equivalent	53.74 Cr	57.5 Cr	41.57 Cr	64.81 Cr

STANDALONE CASH FLOW FOR SEQUENT SCIENTIFIC LIMITED

Year End	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Profit Before Tax	43.45 Cr	15.69 Cr	-9.75 Cr	-23.9 Lk
Adjustment	1.12 Cr	-6.38 Cr	-48.6 Lk	-18.19 Cr
Changes In working Capital	-25.47 Cr	1.81 Cr	48.68 Cr	-10.77 Cr
Cash Flow after changes in Working Capital	19.1 Cr	11.12 Cr	38.45 Cr	-29.2 Cr
Cash Flow from Operating Activities	2.34 Cr	9.36 Cr	37.75 Cr	-26.94 Cr
Cash Flow from Investing Activities	170 Cr	-4.25 Cr	-50.7 Cr	5.47 Cr
Cash Flow from Financing Activitie	-174.78 Cr	7.24 Cr	24.1 Lk	22.32 Cr
Net Cash Inflow / Outflow	-2.44 Cr	12.36 Cr	-12.71 Cr	84.3 Lk
Opening Cash & Cash Equivalents	2.87 Cr	43.5 Lk	12.8 Cr	8.3 Lk
Closing Cash & Cash Equivalent	43.5 Lk	12.8 Cr	8.3 Lk	92.6 Lk

Consolidated Standalone

CONSOLIDATED BALANCE SHEET FOR SEQUENT SCIENTIFIC LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Share Capital	49.67 Cr	49.67 Cr	49.89 Cr	49.89 Cr
Equity - Authorised	80 Cr	80 Cr	80 Cr	80 Cr
Equity - Issued	49.67 Cr	49.67 Cr	49.89 Cr	49.89 Cr
Equity Paid Up	49.67 Cr	49.67 Cr	49.89 Cr	49.89 Cr
Face Value	2	2	2	2
Total Reserves	670.21 Cr	595.64 Cr	592.57 Cr	529.37 Cr
Securities Premium	872.69 Cr	874.26 Cr	900.32 Cr	900.32 Cr
Capital Reserves	2.48 Cr	2.48 Cr	2.48 Cr	2.48 Cr
Profit & Loss Account Balance	59.97 Cr	88.89 Cr	99.68 Cr	95.71 Cr
General Reserves	22.77 Cr	23.29 Cr	23.29 Cr	24.53 Cr
Reserve excluding Revaluation Reserve	670.21 Cr	595.64 Cr	592.57 Cr	529.37 Cr
Shareholder's Funds	727.65 Cr	692.41 Cr	698.78 Cr	656.56 Cr
Minority Interest	48.66 Cr	48.01 Cr	50.41 Cr	56.4 Cr
Secured Loans	62.52 Cr	87.25 Cr	127.17 Cr	123.76 Cr
Term Loans - Banks	61.15 Cr	86.22 Cr	126.8 Cr	83.43 Cr
Term Loans - Institutions	1.37 Cr	1.02 Cr	36.6 Lk	0
Unsecured Loans	31.18 Cr	35.21 Cr	55.63 Cr	18.96 Cr
Loans - Banks	22.71 Cr	27.49 Cr	49.82 Cr	18.01 Cr
Loans - Others	8.47 Cr	7.71 Cr	5.81 Cr	95.3 Lk
Deferred Tax Assets / Liabilities	-13.58 Cr	-23.21 Cr	-33.11 Cr	-71.48 Cr
Deferred Tax Assets	29.98 Cr	31.32 Cr	49.47 Cr	83.03 Cr
Deferred Tax Liability	16.41 Cr	8.1 Cr	16.36 Cr	11.55 Cr
Other Long Term Liabilities	46.27 Cr	44.14 Cr	37.34 Cr	29.1 Cr
Long Term Provisions	26.3 Cr	55.94 Cr	71.08 Cr	21.75 Cr
Total Non-Current Liabilities	152.69 Cr	199.33 Cr	258.11 Cr	122.08 Cr
Trade Payables	229.56 Cr	258.04 Cr	244.34 Cr	260.26 Cr
Sundry Creditors	229.56 Cr	258.04 Cr	244.34 Cr	260.26 Cr
Other Current Liabilities	100.64 Cr	78.99 Cr	76.88 Cr	109.56 Cr
Advances received from customers	5.18 Cr	3.36 Cr	5.46 Cr	8.13 Cr
Interest Accrued But Not Due	26.7 Lk	61.8 Lk	56.4 Lk	99.5 Lk
Short Term Borrowings	102.9 Cr	159.54 Cr	182.09 Cr	245.87 Cr
Secured ST Loans repayable on Demands	57.58 Cr	120.6 Cr	130.53 Cr	182.83 Cr
Working Capital Loans- Sec	57.58 Cr	120.6 Cr	130.53 Cr	182.83 Cr
Short Term Provisions	80.9 Cr	40.77 Cr	55.45 Cr	11.31 Cr
Provision for Tax	75.75 Cr	33.47 Cr	39.03 Cr	3.34 Cr
Total Current Liabilities	514 Cr	537.35 Cr	558.75 Cr	626.99 Cr
Total Liabilities	1443.01 Cr	1477.09 Cr	1566.05 Cr	1462.03 Cr
Gross Block	754.21 Cr	816.26 Cr	939.83 Cr	959.12 Cr
Less: Accumulated Depreciation	217.6 Cr	261.29 Cr	334.52 Cr	367.17 Cr
Net Block	536.61 Cr	554.96 Cr	605.31 Cr	591.95 Cr
Capital Work in Progress	28.78 Cr	8.81 Cr	51.39 Cr	11.08 Cr
Non Current Investments	76.94 Cr	36.79 Cr	50,000	89.3 Lk
Long Term Investment	76.94 Cr	36.79 Cr	50,000	89.3 Lk
Quoted	76.93 Cr	36.79 Cr	0	0
Unquoted	50,000	50,000	50,000	89.3 Lk
Long Term Loans & Advances	32.15 Cr	53.92 Cr	71.33 Cr	18.99 Cr
Other Non Current Assets	79.2 Lk	7.85 Cr	11.55 Cr	11.41 Cr
Total Non-Current Assets	676.33 Cr	665.16 Cr	743.48 Cr	639.17 Cr
Currents Investments	5.66 Cr	1.44 Cr	4.6 Lk	2.61 Cr
Quoted	6.5 Lk	13.8 Lk	4.6 Lk	2.61 Cr
Unquoted	50,000	50,000	50,000	89.3 Lk
Inventories	264.36 Cr	347.97 Cr	346.09 Cr	346.23 Cr
Raw Materials	91.79 Cr	129.05 Cr	141.23 Cr	116.71 Cr
Work-in Progress	41.49 Cr	56.78 Cr	48.91 Cr	53.36 Cr
Finished Goods	46.17 Cr	106.61 Cr	60.23 Cr	122.2 Cr
Stores and Spare	0	0	2.6 Lk	0
Sundry Debtors	346.14 Cr	329.24 Cr	340.96 Cr	335.63 Cr
Debtors more than Six months	0	5.75 Cr	11.35 Cr	20.72 Cr
Debtors Others	351.64 Cr	327.33 Cr	332.62 Cr	318.26 Cr
Cash and Bank	56.2 Cr	59.25 Cr	41.75 Cr	69.83 Cr
Cash in hand	3.8 Lk	6.9 Lk	5.8 Lk	6 Lk
Balances at Bank	56.16 Cr	46.24 Cr	41.67 Cr	69.67 Cr
Other Current Assets	16.82 Cr	7.68 Cr	7.74 Cr	10.37 Cr
Interest accrued on Investments	6.5 Lk	2.9 Lk	50,000	10.2 Lk
Prepaid Expenses	5.64 Cr	5.91 Cr	6.17 Cr	6.7 Cr
Short Term Loans and Advances	77.52 Cr	66.35 Cr	75.9 Cr	46.26 Cr
Advances recoverable in cash or in kind	2.26 Cr	5.13 Cr	6.77 Cr	6.78 Cr
Advance income tax and TDS	53.55 Cr	26 Cr	36.24 Cr	37.2 Lk
Total Current Assets	766.68 Cr	811.93 Cr	812.48 Cr	810.94 Cr
Net Current Assets (Including Current Investments)	252.68 Cr	274.58 Cr	253.73 Cr	183.95 Cr
Total Assets	1443.01 Cr	1477.09 Cr	1566.05 Cr	1462.03 Cr
Contingent Liabilities	2.27 Cr	1.67 Cr	176.33 Cr	4.33 Cr
Total Debt	223.79 Cr	314.89 Cr	397.9 Cr	451.28 Cr
Book Value	28.98	0	0	23.22
Adjusted Book Value	28.98	25.98	25.76	23.22

STANDALONE BALANCE SHEET FOR SEQUENT SCIENTIFIC LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Share Capital	49.67 Cr	49.67 Cr	49.89 Cr	49.89 Cr
Equity - Authorised	80 Cr	80 Cr	80 Cr	80 Cr
Equity - Issued	49.67 Cr	49.67 Cr	49.89 Cr	49.89 Cr
Equity Paid Up	49.67 Cr	49.67 Cr	49.89 Cr	49.89 Cr
Face Value	2	2	2	2
Total Reserves	972.07 Cr	944.32 Cr	952.25 Cr	960.03 Cr
Securities Premium	872.69 Cr	874.26 Cr	900.32 Cr	900.32 Cr
Capital Reserves	1.06 Cr	1.06 Cr	1.06 Cr	1.06 Cr
Profit & Loss Account Balance	28.03 Cr	30.56 Cr	38.76 Cr	42.03 Cr
General Reserves	17.5 Cr	17.86 Cr	17.86 Cr	19.01 Cr
Reserve excluding Revaluation Reserve	972.07 Cr	944.32 Cr	952.25 Cr	960.03 Cr
Shareholder's Funds	1029.51 Cr	1041.09 Cr	1058.36 Cr	1087.23 Cr
Deferred Tax Assets / Liabilities	-1.91 Cr	-6.03 Cr	-12.23 Cr	-11.59 Cr
Deferred Tax Assets	8.79 Cr	8.31 Cr	12.37 Cr	11.59 Cr
Deferred Tax Liability	6.88 Cr	2.28 Cr	14.4 Lk	0
Other Long Term Liabilities	11.7 Lk	77.7 Lk	26.7 Lk	0
Long Term Provisions	6.59 Cr	24.51 Cr	24.4 Cr	2.21 Cr
Total Non-Current Liabilities	4.8 Cr	19.26 Cr	12.44 Cr	-9.38 Cr
Trade Payables	58.75 Cr	57.56 Cr	36.71 Cr	38.45 Cr
Sundry Creditors	58.75 Cr	57.56 Cr	36.71 Cr	38.45 Cr
Other Current Liabilities	2.85 Cr	5.2 Cr	4.67 Cr	12.64 Cr
Advances received from customers	6.5 Lk	9.6 Lk	7.2 Lk	55.6 Lk
Interest Accrued But Not Due	0	0	0	22.4 Lk
Short Term Borrowings	5.22 Cr	15.5 Cr	19.1 Cr	46.46 Cr
Secured ST Loans repayable on Demands	5.22 Cr	15.5 Cr	19.1 Cr	46.46 Cr
Working Capital Loans- Sec	5.22 Cr	15.5 Cr	19.1 Cr	46.46 Cr
Short Term Provisions	29.81 Cr	11.3 Cr	9.77 Cr	61.1 Lk
Provision for Tax	29.15 Cr	9.62 Cr	9.24 Cr	0
Total Current Liabilities	96.62 Cr	89.56 Cr	70.24 Cr	98.16 Cr
Total Liabilities	1130.94 Cr	1149.9 Cr	1141.04 Cr	1176 Cr
Gross Block	102.86 Cr	113.09 Cr	110.96 Cr	87.15 Cr
Less: Accumulated Depreciation	37.08 Cr	46.18 Cr	54.24 Cr	44.62 Cr
Net Block	65.78 Cr	66.9 Cr	56.72 Cr	42.52 Cr
Capital Work in Progress	4.34 Cr	1.4 Cr	2.2 Cr	5.14 Cr
Non Current Investments	685.11 Cr	658.47 Cr	632.47 Cr	640.3 Cr
Long Term Investment	685.11 Cr	658.47 Cr	632.47 Cr	640.3 Cr
Quoted	76.91 Cr	36.77 Cr	0	0
Unquoted	619.42 Cr	621.7 Cr	632.47 Cr	640.3 Cr
Long Term Loans & Advances	230.43 Cr	267.65 Cr	355.33 Cr	382.3 Cr
Other Non Current Assets	28.8 Lk	61.4 Lk	57 Lk	56.4 Lk
Total Non-Current Assets	985.95 Cr	995.04 Cr	1047.29 Cr	1070.83 Cr
Currents Investments	6.5 Lk	13.8 Lk	4.6 Lk	11.3 Lk
Quoted	6.5 Lk	13.8 Lk	4.6 Lk	11.3 Lk
Unquoted	619.42 Cr	621.7 Cr	632.47 Cr	640.3 Cr
Inventories	45.79 Cr	67.99 Cr	47.95 Cr	34.54 Cr
Raw Materials	10.41 Cr	12.95 Cr	12.08 Cr	4.52 Cr
Work-in Progress	23.72 Cr	28.69 Cr	17.51 Cr	13.3 Cr
Finished Goods	10.07 Cr	25.96 Cr	17.86 Cr	11.81 Cr
Stores and Spare	0	0	27 Lk	28.4 Lk
Sundry Debtors	61.44 Cr	52.42 Cr	13.65 Cr	44.79 Cr
Debtors more than Six months	0	6.1 Lk	1.2 Lk	63.7 Lk
Debtors Others	61.5 Cr	52.42 Cr	13.65 Cr	44.17 Cr
Cash and Bank	74 Lk	12.89 Cr	17.7 Lk	95.5 Lk
Cash in hand	30,000	30,000	0	0
Balances at Bank	73.7 Lk	20.8 Lk	17.7 Lk	95.5 Lk
Other Current Assets	3.56 Cr	1.74 Cr	99.5 Lk	2.84 Cr
Interest accrued on Investments	1.2 Lk	30,000	30,000	20,000
Prepaid Expenses	1.38 Cr	1.41 Cr	92.3 Lk	1.44 Cr
Short Term Loans and Advances	33.4 Cr	19.69 Cr	20.84 Cr	13.54 Cr
Advances recoverable in cash or in kind	21.4 Lk	57.9 Lk	94 Lk	1.2 Cr
Advance income tax and TDS	26.43 Cr	9 Cr	8.64 Cr	0
Total Current Assets	144.99 Cr	154.86 Cr	83.66 Cr	96.78 Cr
Net Current Assets (Including Current Investments)	48.37 Cr	65.31 Cr	13.42 Cr	-1.38 Cr
Total Assets	1130.94 Cr	1149.9 Cr	1141.04 Cr	1176 Cr
Contingent Liabilities	0	0	262.71 Cr	1.2 Lk
Total Debt	5.22 Cr	15.5 Cr	19.1 Cr	46.46 Cr
Book Value	41.14	0	40.18	40.49
Adjusted Book Value	41.14	40.02	40.18	40.49

Consolidated Standalone

FINANCIAL RATIOS (CONSOLIDATED) FOR SEQUENT SCIENTIFIC LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Operational & Financial Ratios
Earnings Per Share (Rs)	3.84	1.66	-4.86	-1.44
CEPS(Rs)	6.24	3.87	-2.66	1.28
DPS(Rs)	0.5	0	0	0
Book NAV/Share(Rs)	28.98	25.98	25.76	23.22
Tax Rate(%)	23.55	15.6	11.39	45.81
Margin Ratios
Core EBITDA Margin(%)	15.28	7.74	0.82	4.35
EBIT Margin(%)	11.6	4.9	-7.02	-0.46
Pre Tax Margin(%)	9.84	3.78	-9.47	-3.87
PAT Margin (%)	7.53	3.19	-8.39	-2.1
Cash Profit Margin (%)	11.17	6.81	-4.56	2.26
Performance Ratios
ROA(%)	7.19	3.09	-7.99	-2.01
ROE(%)	15	6.6	-18.95	-4.85
ROCE(%)	16.25	7.06	-9.71	-0.6
Asset Turnover(x)	0.96	0.97	0.95	0.96
Sales/Fixed Asset(x)	1.83	1.8	1.65	1.49
Working Capital/Sales(x)	5.49	5.15	5.73	7.67
Efficiency Ratios
Fixed Capital/Sales(x)	0.55	0.56	0.61	0.67
Receivable days	87.43	87.24	84.11	87.51
Inventory Days	63.61	79.1	87.1	89.54
Payable days	71.27	111.61	109.97	121.21
Valuation Parameters
PER(x)	62.69	80.56	0	0
PCE(x)	38.59	34.56	-27.32	90.08
Price/Book(x)	8.31	5.15	2.82	4.96
Yield(%)	0.21	0	0	0
EV/Net Sales(x)	4.52	2.53	1.52	2.38
EV/Core EBITDA(x)	27.9	29.76	118.11	45.01
EV/EBIT(x)	38.2	51.75	-21.21	-496.55
EV/CE(x)	4.26	2.42	1.38	2.94
M Cap / Sales	4.39	2.35	1.27	2.1
Growth Ratio
Net Sales Growth(%)	15.47	3.76	0.57	-3.6
Core EBITDA Growth(%)	22.18	-45.45	-84.74	294.5
EBIT Growth(%)	24.06	-57.05	-248.67	93.58
PAT Growth(%)	27.31	-56.86	-372.49	75.72
EPS Growth(%)	36.53	-56.78	-394.58	70.4
Financial Stability Ratios
Total Debt/Equity(x)	0.31	0.49	0.62	0.78
Current Ratio(x)	1.49	1.51	1.45	1.29
Quick Ratio(x)	0.98	0.86	0.83	0.74
Interest Cover(x)	6.6	4.38	-2.88	-0.14
Total Debt/Mcap(x)	0.04	0.09	0.22	0.16

FINANCIAL RATIOS (STANDALONE) FOR SEQUENT SCIENTIFIC LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Operational & Financial Ratios
Earnings Per Share (Rs)	1.29	0.6	-0.24	0.02
CEPS(Rs)	1.66	0.98	0.12	0.38
DPS(Rs)	0.5	0	0	0
Book NAV/Share(Rs)	41.14	40.02	40.18	40.49
Tax Rate(%)	21.46	5.68	37.62	360.25
Margin Ratios
Core EBITDA Margin(%)	13.13	-5.43	-11.73	-15.46
EBIT Margin(%)	16.21	7.85	-3.21	2.39
Pre Tax Margin(%)	15.22	7.12	-4.33	-0.14
PAT Margin (%)	11.95	6.72	-2.7	0.36
Cash Profit Margin (%)	15.35	11.07	1.35	5.54
Performance Ratios
ROA(%)	3.01	1.3	-0.53	0.05
ROE(%)	3.39	1.47	-0.61	0.06
ROCE(%)	4.45	1.65	-0.68	0.37
Asset Turnover(x)	0.25	0.19	0.2	0.15
Sales/Fixed Asset(x)	2.66	2.04	2.01	1.74
Working Capital/Sales(x)	5.55	3.37	16.78	-124.87
Efficiency Ratios
Fixed Capital/Sales(x)	0.38	0.49	0.5	0.57
Receivable days	69.43	94.31	53.54	61.84
Inventory Days	52.44	94.25	93.97	87.31
Payable days	99.34	195.35	126.58	127.14
Valuation Parameters
PER(x)	186.32	224.57	0	4630.52
PCE(x)	145.08	136.24	596.59	300.77
Price/Book(x)	5.86	3.34	1.81	2.85
Yield(%)	0.21	0	0	0
EV/Net Sales(x)	22.56	15.14	8.22	17.34
EV/Core EBITDA(x)	108.36	123.67	972.14	151.24
EV/EBIT(x)	137.44	192.24	-252.95	708.74
EV/CE(x)	5.29	2.89	1.6	2.58
M Cap / Sales	22.54	15.13	8.13	17.07
Growth Ratio
Net Sales Growth(%)	16.77	-17.26	1.39	-24.32
Core EBITDA Growth(%)	50.16	-51.33	-93	926.36
EBIT Growth(%)	56.45	-60.29	-141.81	156.99
PAT Growth(%)	50.48	-53.92	-141.08	110.23
EPS Growth(%)	50.48	-53.92	-140.91	110.21
Financial Stability Ratios
Total Debt/Equity(x)	0.01	0.02	0.02	0.05
Current Ratio(x)	1.5	1.73	1.19	0.99
Quick Ratio(x)	1.03	0.97	0.51	0.63
Interest Cover(x)	16.26	10.75	-2.88	0.95
Total Debt/Mcap(x)	0	0	0.01	0.02

SHARE HOLDING PATTERN FOR SEQUENT SCIENTIFIC LIMITED

Date	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Promoters %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	52.78	0.00
FII %	6.45	6.57	6.25	5.89	6.27	6.03	6.11	6.16	5.69	6.45
DII %	0.90	1.12	1.35	1.46	1.92	2.20	2.21	2.43	2.37	2.58
Public %	38.49	37.86	38.15	38.39	38.03	37.96	33.86	33.46	33.46	30.80

PEER COMPARISON FOR SEQUENT SCIENTIFIC LIMITED

No.	Name
1	AMBALAL SARABHAI ENTERPRISES LTD
2	Cipla Limited
3	Dr. Reddy's Laboratories Limited
4	Procter & Gamble Health Limited
5	J.K.PHARMACHEM LTD
6	Lupin Limited
7	Lyka Labs Limited
8	MESCO PHARMACEUTICALS LTD
9	Morepen Laboratories Limited
10	Piramal Enterprises Limited
11	Torrent Pharmaceuticals Limited
12	Abbott India Limited
13	GlaxoSmithKline Pharmaceuticals Limited
14	Sanofi India Limited
15	Pfizer Limited
16	Bliss GVS Pharma Limited
17	Alembic Limited
18	Unichem Laboratories Limited
19	AstraZeneca Pharma India Limited
20	GUJARAT THEMIS BIOSYN LTD
21	JB Chemicals & Pharmaceuticals Limited
22	TTK Healthcare Limited
23	Jagsonpal Pharmaceuticals Limited
24	Gufic Biosciences Limited
25	Sequent Scientific Limited
26	Albert David Limited
27	IOL Chemicals and Pharmaceuticals Limited
28	Wanbury Limited
29	Kopran Limited
30	Aarti Drugs Limited
31	Orchid Pharma Limited
32	Biofil Chemicals & Pharmaceuticals Limited
33	Marksans Pharma Limited
34	IPCA Laboratories Limited
35	Kilitch Drugs (India) Limited
36	Krebs Biochemicals and Industries Limited
37	Neuland Laboratories Limited
38	Ind-Swift Limited
39	Hester Biosciences Limited
40	Parenteral Drugs (India) Limited
41	Sun Pharmaceutical Industries Limited
42	Hikal Limited
43	Caplin Point Laboratories Limited
44	Aurobindo Pharma Limited
45	Natco Pharma Limited
46	Bal Pharma Limited
47	BDH INDUSTRIES LTD
48	Venus Remedies Limited
49	Jubilant Pharmova Limited
50	Themis Medicare Limited

CORPORATE ACTIONS FOR SEQUENT SCIENTIFIC

Exchange Date	Purpose	Book Closure Dates
BSE 09-Aug-2024	Board Meeting - Quarterly Results	14-Aug-2024
BSE 08-May-2024	Board Meeting - Final Dividend & Audited Results	15-May-2024
BSE 06-Feb-2024	Board Meeting - Quarterly Results	13-Feb-2024
BSE 30-Oct-2023	Board Meeting - Quarterly Results	06-Nov-2023
BSE 04-Aug-2023	Board Meeting - Quarterly Results	10-Aug-2023
BSE 16-May-2023	Board Meeting - Dividend & Audited Results	23-May-2023
BSE 08-Mar-2023	SAST - We refer to our announcement on November 07, 2022, regarding acquisition of 100% stake in Tineta Pharma Private limited ('Tineta') by the Company, it is hereby informed that the transaction contemplated under the Share Purchase Agreement has not been materialized. Therefore, the Company will not acquire Tineta and the Share Purchase Agreement entered by the Company with Tineta and its Promoters on...
BSE 08-Feb-2023	Board Meeting - Quarterly Results	14-Feb-2023
BSE 07-Nov-2022	SAST - Sequent Scientific Limited has informed the Exchange that the Board of Directors of the Company at their meeting held today, have inter alia considered and approved the following: 1. Acquisition of entire 100% stake in Tineta Pharma Private Limited ('Tineta') 2. Issuance of equity shares of face value Rs. 2/- each fully paid up of the Company for a value of Rs. 65,00,00,000/- (Rupees Sixty-Five Cr...
BSE 02-Nov-2022	Board Meeting - Quarterly Results & Preferential Issue of shares	07-Nov-2022
BSE 01-Aug-2022	Board Meeting - Quarterly Results	08-Aug-2022
BSE 18-May-2022	Board Meeting - Audited Results	25-May-2022
BSE 04-Feb-2022	Board Meeting - Quarterly Results	11-Feb-2022
BSE 16-Dec-2021	SAST - We wish to inform you that Evance Saude Animal Health Ltda ('Evance'), Brazil, a subsidiary of the Company has entered into a definitive agreement for acquisition of 100% stake in Nourrie Sa?de e Nutri??o Animal Ltda ('Nourrie'). In this regard, please find attached: a. Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Re...
BSE 25-Oct-2021	Board Meeting - Quarterly Results	01-Nov-2021

CORPORATE ANNOUNCEMENTS FOR SEQUENT SCIENTIFIC

Exchange Date	Category File	Description
BSE 30-Oct-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS Allotment of ESOP
BSE 29-Oct-2024	Intimation FILE	Shareholder Meeting / Postal Ballot-Notice of Postal Ballot Shifting of registered office of the Company from state Maharashtra to state Telangana
BSE 28-Oct-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Change in Directorate Completion of tenure of Dr. Kausalya Santhanam as Independent Director of the Company
BSE 17-Oct-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS ESOP Allotment
BSE 14-Oct-2024	General Announcements FILE	Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Compliance -Certificate under Reg. 74(5) of SEBI (DP) Regulation 2018 for quarter and half year ended September 30 2024
BSE 09-Oct-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Investor/ Analyst Meet
BSE 04-Oct-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome Transcript -Investor call dated 01/10/2024
BSE 02-Oct-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome Audio recording of conference call -October 01 2024
BSE 27-Sep-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Investor Presentation Investor Presentation
BSE 26-Sep-2024	General Announcements FILE	Intimation Under Regulation 30 Of SEBI (Listing Obligations & Disclosure Requirements) 2015 - Board Approves Change In The Registered Office And Consequent Amendment To The Memorandum Of Association Of The Company Board Approves Change in the Registered Office and consequent amendment to the memorandum of Association of the Company.
BSE 26-Sep-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Intimation of Conference Call
BSE 26-Sep-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Scheme of Arrangement Scheme of arrangement
BSE 26-Sep-2024	Intimation FILE	Closure of Trading Window Closure of Trading Window
BSE 23-Sep-2024	Outcome FILE	Shareholder Meeting / Postal Ballot-Outcome of AGM Clarifications on delayed submission of the proceedings of the Thirty-Ninth Annual General Meeting of the Company.
BSE 19-Sep-2024	Outcome FILE	Shareholder Meeting / Postal Ballot-Scrutinizer''s Report Voting Results and scrutinizers Report
BSE 18-Sep-2024	Outcome FILE	Shareholder Meeting / Postal Ballot-Outcome of AGM Summary of proceedings of the Thirty-Ninth Annual General Meeting of the Company.
BSE 10-Sep-2024	General Announcements FILE	Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations & Disclosure Requirements) Regulations 2015 Intimation under Regulation 30 of the securities and Exchange Board of India (Listing Obligation & Disclosure Requirement) Regulation 2015:ESOP Grant under SeQuent Scientific Employee Stock Option Plan 2020
BSE 27-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Newspaper Publication AGM Notice-Newspaper Publication
BSE 26-Aug-2024	General Announcements FILE	Business Responsibility and Sustainability Reporting (BRSR) BRSR-FY 2023-24
BSE 26-Aug-2024	General Announcements FILE	Reg. 34 (1) Annual Report. SEQUENT SCIENTIFIC LIMITED-Annual Report 2023-24
BSE 26-Aug-2024	Intimation FILE	Notice Of 39Th Annual General Meeting And Annual Report For The FY 2023-24 Notice of 39th Annual General Meeting (AGM) and Annual Report for FY 2023-24: The AGM of the Company will be held on Tuesday September 17 2024 at 04:30 P.M (IST) through Video Conferencing/ other Audio Visual Means to transact the businesses as set forth in the Notice of AGM
BSE 21-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Earnings Call Transcript Earnings call transcript Dated-August 16 2024
BSE 19-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Press Release / Media Release Press Release- Receive prequalification approval from WHO for albendazole API
BSE 16-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome Investor call outcome Website Link of recording
BSE 16-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Newspaper Publication Newspaper Publication Unaudited Results Q1FY25
BSE 15-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Investor Presentation Investor Presentation
BSE 14-Aug-2024	Outcome FILE	Board Meeting Outcome for Sequent Outcome Sequent Board Meeting Outcome Q1 FY 2024-25 Result and Re-appointment of Auditor
BSE 14-Aug-2024	Outcome FILE	Sequent Results Q1 FY2024-25 Sequent Result Q1 FY 2024-25
BSE 09-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 kindly note that the Company has as a part of its investors engagement activities scheduled a conference call with the Analysts / Investors on Friday August 16 2024 to discuss its Q1FY25 financial results.
BSE 09-Aug-2024	Intimation FILE	Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29(1) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 SEQUENT SCIENTIFIC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2024 inter alia to consider and approve Pursuant to Regulation 29(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 this is to inform you that the Meeting of the Board of Directors of SeQuent Scientific Limited is scheduled to be held on Wednesday August 14 2024 to consider and approve the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended June 30 2024.

INSIDER TRADING FOR SEQUENT SCIENTIFIC

Exchange Dates	Activity	Qty & Price (%)	Person / Organisation
BSE 29-Mar-2022 29-Mar-2022	Sell Market	291,476 @ 0.00 (0.12 %)	Manish Gupta
BSE 28-Mar-2022 28-Mar-2022	Sell Market	98,032 @ 0.00 (0.03 %)	Manish Gupta
BSE 30-Mar-2022 30-Mar-2022	Sell Market	103,498 @ 0.00 (0.05 %)	Manish Gupta
BSE 31-Mar-2022 31-Mar-2022	Sell Market	52,634 @ 0.00 (0.01 %)	Manish Gupta
BSE 22-Mar-2022 22-Mar-2022	Sell Market	66,421 @ 0.00 (0.02 %)	Manish Gupta
BSE 23-Mar-2022 23-Mar-2022	Sell Market	286,500 @ 0.00 (0.11 %)	Manish Gupta
BSE 24-Mar-2022 24-Mar-2022	Sell Market	300,000 @ 0.00 (0.12 %)	Manish Gupta
BSE 08-Mar-2022 08-Mar-2022	Sell Market	6,317 @ 0.00 (0.00 %)	Manish Gupta
BSE 09-Mar-2022 09-Mar-2022	Sell Market	54,230 @ 0.00 (0.02 %)	Manish Gupta
BSE 04-Mar-2022 04-Mar-2022	Sell Market	20,000 @ 0.00 (0.01 %)	Manish Gupta
BSE 28-Feb-2022 28-Feb-2022	Sell Market	100,000 @ 0.00 (0.04 %)	Manish Gupta
BSE 02-Mar-2022 02-Mar-2022	Sell Market	52,327 @ 0.00 (0.02 %)	Manish Gupta
BSE 03-Mar-2022 03-Mar-2022	Sell Market	17,000 @ 0.00 (0.01 %)	Manish Gupta
BSE 21-Feb-2022 21-Feb-2022	Sell Market	128,787 @ 0.00 (0.05 %)	Manish Gupta
BSE 23-Feb-2022 23-Feb-2022	Sell Market	70,949 @ 0.00 (0.03 %)	Manish Gupta
BSE 23-Feb-2022 23-Feb-2022	Sell Market	20,000 @ 0.00 (0.01 %)	Sharat Narasapur
BSE 18-Feb-2022 18-Feb-2022	Sell Market	18,006 @ 0.00 (0.01 %)	Manish Gupta
BSE 16-Feb-2022 16-Feb-2022	Sell Market	25,000 @ 0.00 (0.01 %)	Sharat Narasapur
BSE 17-Feb-2022 17-Feb-2022	Sell Market	20,000 @ 0.00 (0.00 %)	Sharat Narasapur
BSE 18-Feb-2022 18-Feb-2022	Sell Market	5,000 @ 0.00 (0.01 %)	Sharat Narasapur
BSE 16-Feb-2022 16-Feb-2022	Sell Market	60,000 @ 0.00 (0.03 %)	Tushar P Mistry
BSE 16-Feb-2022 16-Feb-2022	Sell Market	150,000 @ 0.00 (0.06 %)	Manish Gupta
BSE 31-Dec-2021 31-Dec-2021	Sell Market	11,260 @ 0.00 (0.00 %)	Amit Shah
BSE 29-Dec-2021 29-Dec-2021	Sell Market	1,788 @ 0.00 (0.00 %)	Gaurav Kumar Agrawal
BSE 30-Dec-2021 30-Dec-2021	Sell Market	8,212 @ 0.00 (0.00 %)	Gaurav Kumar Agrawal
BSE 28-Dec-2021 28-Dec-2021	Sell Market	10,000 @ 0.00 (0.00 %)	Ashish Kakabalia
BSE 30-Dec-2021 30-Dec-2021	Sell Market	15,000 @ 0.00 (0.00 %)	Ashish Kakabalia
BSE 31-Dec-2021 31-Dec-2021	Sell Market	10,000 @ 0.00 (0.00 %)	Ashish Kakabalia
BSE 28-Dec-2021 28-Dec-2021	Sell Market	10,000 @ 0.00 (0.00 %)	Kalpana Mukherjee
BSE 29-Dec-2021 29-Dec-2021	Sell Market	10,000 @ 0.00 (0.00 %)	Kalpana Mukherjee

BULK BLOCK DEALS FOR SEQUENT SCIENTIFIC LIMITED

Exchange Dates	Activity	Qty & Price (%)	Person / Organisation
BSE 09-Dec-2021	Buy BULK	1,507,365 @ 165.04	GKN SECURITIES
BSE 09-Dec-2021	Sell BULK	43,663 @ 170.11	GKN SECURITIES
BSE 09-Dec-2021	Sell BULK	14,685,986 @ 157.02	INFINITY HOLDINGS
BSE 09-Dec-2021	Buy BULK	1,283,113 @ 155.01	MANSI SHARE & STOCK ADVISORS PRIVATE LIMITED
BSE 09-Dec-2021	Sell BULK	275,412 @ 162.34	MANSI SHARE & STOCK ADVISORS PRIVATE LIMITED
BSE 09-Dec-2021	Buy BULK	1,605,698 @ 164.74	MILLENNIUM STOCK BROKING PVT LTD
BSE 09-Dec-2021	Sell BULK	184,018 @ 170.23	MILLENNIUM STOCK BROKING PVT LTD

DIVIDEND BY SEQUENT SCIENTIFIC LIMITED

Ex Dividend Date	Dividend Type	Dividend
08-Sep-2021	DIVIDEND	0.5

SPLIT / BONUS BY SEQUENT SCIENTIFIC LIMITED

No Split / Bonus details found

Data feed Source : www.accordfintech.com, NSE DATA Feed & BSE Data Feed

Facebook

Twitter

To TOP

Sequent Scientific Limited

Sequent Scientific share price

CONSOLIDATED QUARTERLY RESULT FOR SEQUENT SCIENTIFIC LIMITED

STANDALONE QUARTERLY RESULT FOR SEQUENT SCIENTIFIC LIMITED

CONSOLIDATED ANNUAL RESULT FOR SEQUENT SCIENTIFIC LIMITED

STANDALONE ANNUAL RESULT FOR SEQUENT SCIENTIFIC LIMITED

CONSOLIDATED PROFIT / LOSS FOR SEQUENT SCIENTIFIC LIMITED

STANDALONE PROFIT / LOSS FOR SEQUENT SCIENTIFIC LIMITED

CONSOLIDATED CASH FLOW FOR SEQUENT SCIENTIFIC LIMITED

STANDALONE CASH FLOW FOR SEQUENT SCIENTIFIC LIMITED

CONSOLIDATED BALANCE SHEET FOR SEQUENT SCIENTIFIC LIMITED

STANDALONE BALANCE SHEET FOR SEQUENT SCIENTIFIC LIMITED

FINANCIAL RATIOS (CONSOLIDATED) FOR SEQUENT SCIENTIFIC LIMITED

FINANCIAL RATIOS (STANDALONE) FOR SEQUENT SCIENTIFIC LIMITED

SHARE HOLDING PATTERN FOR SEQUENT SCIENTIFIC LIMITED

PEER COMPARISON FOR SEQUENT SCIENTIFIC LIMITED

CORPORATE ACTIONS FOR SEQUENT SCIENTIFIC

CORPORATE ANNOUNCEMENTS FOR SEQUENT SCIENTIFIC

INSIDER TRADING FOR SEQUENT SCIENTIFIC

BULK BLOCK DEALS FOR SEQUENT SCIENTIFIC LIMITED

DIVIDEND BY SEQUENT SCIENTIFIC LIMITED

SPLIT / BONUS BY SEQUENT SCIENTIFIC LIMITED